For instance, Ferraldeschi et al. showed in 2015 that loss of PTEN was associated with a shorter duration of treatment and overall survival among 144 prostate cancer patients receiving hormonal therapy [7]. This evidence concerns the gene PTEN and prostate carcinoma.